Last reviewed · How we verify

Coalition for National Trauma Research — Portfolio Competitive Intelligence Brief

Coalition for National Trauma Research pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Pathogen-Reduced Plasma Pathogen-Reduced Plasma marketed Blood product / Plasma derivative Hematology / Transfusion Medicine

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Baxter Healthcare Corporation · 1 shared drug class
  2. Erasmus Medical Center · 1 shared drug class
  3. Rigshospitalet, Denmark · 1 shared drug class
  4. Rutgers, The State University of New Jersey · 1 shared drug class
  5. Vascular Solutions LLC · 1 shared drug class
  6. Vastra Gotaland Region · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Coalition for National Trauma Research:

Cite this brief

Drug Landscape (2026). Coalition for National Trauma Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/coalition-for-national-trauma-research. Accessed 2026-05-16.

Related